As of 2026-04-19, the Relative Valuation of 10X Genomics Inc (TXG) is (8.28) USD. This relative valuation is based on P/E multiples. With the latest stock price at 26.08 USD, the upside of 10X Genomics Inc based on Relative Valuation is -131.8%.
The range of the Relative Valuation is (7.68) - (8.36) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 22.5x - 27.7x | 25.4x |
| Forward P/E multiples | 21.0x - 24.5x | 23.2x |
| Fair Price | (7.68) - (8.36) | (8.28) |
| Upside | -129.4% - -132.1% | -131.8% |
| Date | P/E |
| 2026-04-17 | -76.51 |
| 2026-04-16 | -74.05 |
| 2026-04-15 | -74.37 |
| 2026-04-14 | -72.76 |
| 2026-04-13 | -69.18 |
| 2026-04-10 | -68.27 |
| 2026-04-09 | -67.48 |
| 2026-04-08 | -67.54 |
| 2026-04-07 | -64.02 |
| 2026-04-06 | -64.22 |
| 2026-04-02 | -65.51 |
| 2026-04-01 | -64.69 |
| 2026-03-31 | -62.28 |
| 2026-03-30 | -58.12 |
| 2026-03-27 | -57.15 |
| 2026-03-26 | -59.94 |
| 2026-03-25 | -61.35 |
| 2026-03-24 | -58.12 |
| 2026-03-23 | -56.15 |
| 2026-03-20 | -53.95 |
| 2026-03-19 | -53.92 |
| 2026-03-18 | -50.90 |
| 2026-03-17 | -53.07 |
| 2026-03-16 | -48.97 |
| 2026-03-13 | -55.13 |
| 2026-03-12 | -55.57 |
| 2026-03-11 | -60.03 |
| 2026-03-10 | -60.03 |
| 2026-03-09 | -61.35 |
| 2026-03-06 | -61.05 |
| 2026-03-05 | -63.49 |
| 2026-03-04 | -65.63 |
| 2026-03-03 | -66.36 |
| 2026-03-02 | -67.89 |
| 2026-02-27 | -67.62 |
| 2026-02-26 | -64.93 |
| 2026-02-25 | -57.68 |
| 2026-02-24 | -56.04 |
| 2026-02-23 | -55.42 |
| 2026-02-20 | -55.39 |
| 2026-02-19 | -56.30 |
| 2026-02-18 | -57.41 |
| 2026-02-17 | -54.63 |
| 2026-02-13 | -53.16 |
| 2026-02-12 | -51.37 |
| 2026-02-11 | -56.18 |
| 2026-02-10 | -56.18 |
| 2026-02-09 | -54.39 |
| 2026-02-06 | -54.60 |
| 2026-02-05 | -51.93 |